Antibodies targeted against LOXL-2 for the treatment of collagen-associated pathologies
US10040868B2 · kind B2 · utility
1Cited by
3References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 24, 2014 |
| Grant date | Aug 7, 2018 |
| Priority date | — |
| Expiry date | Jul 24, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An article of manufacture is disclosed which comprises at least two active agents, wherein a first of the two active agents comprises an anti-cancer agent or an antifibrotic agent and a second of the at least two active agents downregulates the activity and/or expression of lysyl-oxidase like protein-2 (LOXL-2) and which is capable of altering the structure of the extracellular matrix.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.